Aspirin modulates ZNF24 to attenuate the NF-κB/PD-L1 axis in hepatocellular carcinoma
PD-L1-mediated immune evasion is a central obstacle to effective immunotherapy in hepatocellular carcinoma (HCC), yet the upstream transcriptional programs that sustain nuclear factor kappa-B (NF-κB)-driven PD-L1 expression remain incompletely defined. Here, we identify zinc finger protein 24 (ZNF24) as a previously uncharacterized transcriptional regulator associated with the NF-κB/PD-L1 axis in HCC and provide evidence that aspirin treatment is associated with reduced ZNF24, p65, and PD-L1 expression at multiple levels. Integrated transcriptomic profiling and molecular docking were used to identify aspirin-responsive zinc finger proteins in HCC cells. A diethylnitrosamine-induced rat model validated findings in vivo. Mechanistic studies included chromatin immunoprecipitation, dual-luciferase reporter assays, lentiviral-mediated ZNF24 overexpression in HepG2 and Hep3B cells, and Western blotting. Molecular docking predicted the highest aspirin binding affinity for the ZNF24 SCAN domain (− 8.4 kcal/mol) among candidate zinc finger proteins. Aspirin significantly reduced hepatic ZNF24, phosphorylated p65, and PD-L1 expression in vivo. Chromatin immunoprecipitation and luciferase assays were consistent with ZNF24 binding the p65 promoter and activating NF-κB signaling transcriptionally, upregulating PD-L1. ZNF24 overexpression accelerated proliferation, migration, and invasion of hepatocellular carcinoma cells while elevating p65 and PD-L1; these effects were attenuated by aspirin (up to 5 mM) or the NF-κB inhibitor SN50. A linear-regression-based computational model of downregulate ZNF24 expression in a hepatocellular carcinoma patient cohort predicted downregulation of p65 (− 9.5%) and PD-L1 (− 23.1%). Elevated ZNF24 correlated with advanced tumor stage, histological grade, and immune checkpoint markers. Aspirin suppresses the ZNF24/NF-κB/PD-L1 signaling axis in HCC, implicating ZNF24 as a candidate upstream mediator. These findings provide a translational rationale for aspirin as an adjunct to immunotherapy in HCC, subject to further mechanistic and immune-functional validation.
Authors
- Chenrui Liu (ORCID: https://orcid.org/0009-0003-3393-0394)
- Shuangsuo Dang (ORCID: https://orcid.org/0000-0002-9257-5711)
- Yaping Li
- MuQi Wang
- Mei Li (ORCID: https://orcid.org/0000-0001-8634-2252)
- Yang Liu (ORCID: https://orcid.org/0000-0002-5636-030X)
- Yikai Wang (ORCID: https://orcid.org/0000-0001-6709-1777)
- Yindi Tian
- Xiaoli Jia
- Meng Zhang
- Juanjuan Shi
- Wenjun Wang
- Luna Liu
Institutions
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s00262-026-04641-3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00